Tags

Type your tag names separated by a space and hit enter

Clinical use of anti-DFS70 autoantibodies.
Rheumatol Int. 2019 Aug; 39(8):1423-1429.RI

Abstract

The dense fine speckled (DFS) nuclear pattern is one of the most common indirect immunofluorescence (IIF) patterns detected during routine anti-nuclear antibody (ANA) screening. There is a negative association between anti-DFS70 status and systemic autoimmune rheumatic disease (SARD), especially in the absence of concomitant SARD-specific autoantibodies. The purpose of this study was to determine the need for confirming anti-DFS70 status when a DFS pattern is observed in IIF-ANA. The frequency of anti-DFS70 detection on Western blot and the positive rate of connective tissue disease (CTD)-related autoantibody screening with a fluorescence-based enzyme immunoassay was evaluated in DFS (n = 182) and non-DFS (n = 359) groups. Specific autoantibodies against 15 autoantigens were identified by line immunoassay. We evaluated the frequency of cases of DFS mistaken for non-DFS and non-DFS cases mistaken for DFS, as well as the clinical impacts of these misinterpretations. Among cases of IIF-ANA with an observable DFS pattern, 68.1% had only anti-DFS70 without CTD-related autoantibodies, 20.3% were false positive for IIF-ANA, and the remaining 11.5% had CTD-related autoantibodies independent of anti-DFS70 status. These results indicated that CTD-related autoantibodies may be present with or without anti-DFS70 even if a DFS pattern is observed in IIF-ANA. Among patients who are ANA negative or have a low probability of SARD, an anti-DFS70 confirmation test has no clinical benefit and cannot replace specific tests for detecting CTD-related autoantibodies. Specific tests to detect CTD-related autoantibodies should be performed instead of anti-DFS70 confirmation tests when a DFS pattern is observed in IIF-ANA.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kang SY
Department of Laboratory Medicine, KyungHee University School of Medicine, 892, Dongnam-ro, Gangdong-gu, Seooul, 05278, South Korea. sykangmd@daum.net.
Lee WI
Department of Laboratory Medicine, KyungHee University School of Medicine, 892, Dongnam-ro, Gangdong-gu, Seooul, 05278, South Korea.
Kim MH
Department of Laboratory Medicine, KyungHee University School of Medicine, 892, Dongnam-ro, Gangdong-gu, Seooul, 05278, South Korea.
La Jeon Y
Department of Laboratory Medicine, KyungHee University Hospital at Gangdong, Seoul, South Korea.

MeSH

Adaptor Proteins, Signal TransducingAdolescentAdultAgedAged, 80 and overAntibodies, AntinuclearAntigens, NuclearAutoantigensBiomarkersBlotting, WesternChildChild, PreschoolConnective Tissue DiseasesDiagnostic ErrorsFalse Positive ReactionsFemaleFluorescent Antibody Technique, IndirectHumansImmunoenzyme TechniquesMaleMiddle AgedPredictive Value of TestsReproducibility of ResultsTranscription FactorsYoung Adult

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30972541

Citation

Kang, So Young, et al. "Clinical Use of anti-DFS70 Autoantibodies." Rheumatology International, vol. 39, no. 8, 2019, pp. 1423-1429.
Kang SY, Lee WI, Kim MH, et al. Clinical use of anti-DFS70 autoantibodies. Rheumatol Int. 2019;39(8):1423-1429.
Kang, S. Y., Lee, W. I., Kim, M. H., & La Jeon, Y. (2019). Clinical use of anti-DFS70 autoantibodies. Rheumatology International, 39(8), 1423-1429. https://doi.org/10.1007/s00296-019-04299-4
Kang SY, et al. Clinical Use of anti-DFS70 Autoantibodies. Rheumatol Int. 2019;39(8):1423-1429. PubMed PMID: 30972541.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical use of anti-DFS70 autoantibodies. AU - Kang,So Young, AU - Lee,Woo In, AU - Kim,Myeong Hee, AU - La Jeon,You, Y1 - 2019/04/10/ PY - 2019/02/24/received PY - 2019/04/02/accepted PY - 2019/4/12/pubmed PY - 2020/3/11/medline PY - 2019/4/12/entrez KW - Anti-nuclear antibody KW - Dense fine speckled 70 protein KW - Indirect immunofluorescence SP - 1423 EP - 1429 JF - Rheumatology international JO - Rheumatol Int VL - 39 IS - 8 N2 - The dense fine speckled (DFS) nuclear pattern is one of the most common indirect immunofluorescence (IIF) patterns detected during routine anti-nuclear antibody (ANA) screening. There is a negative association between anti-DFS70 status and systemic autoimmune rheumatic disease (SARD), especially in the absence of concomitant SARD-specific autoantibodies. The purpose of this study was to determine the need for confirming anti-DFS70 status when a DFS pattern is observed in IIF-ANA. The frequency of anti-DFS70 detection on Western blot and the positive rate of connective tissue disease (CTD)-related autoantibody screening with a fluorescence-based enzyme immunoassay was evaluated in DFS (n = 182) and non-DFS (n = 359) groups. Specific autoantibodies against 15 autoantigens were identified by line immunoassay. We evaluated the frequency of cases of DFS mistaken for non-DFS and non-DFS cases mistaken for DFS, as well as the clinical impacts of these misinterpretations. Among cases of IIF-ANA with an observable DFS pattern, 68.1% had only anti-DFS70 without CTD-related autoantibodies, 20.3% were false positive for IIF-ANA, and the remaining 11.5% had CTD-related autoantibodies independent of anti-DFS70 status. These results indicated that CTD-related autoantibodies may be present with or without anti-DFS70 even if a DFS pattern is observed in IIF-ANA. Among patients who are ANA negative or have a low probability of SARD, an anti-DFS70 confirmation test has no clinical benefit and cannot replace specific tests for detecting CTD-related autoantibodies. Specific tests to detect CTD-related autoantibodies should be performed instead of anti-DFS70 confirmation tests when a DFS pattern is observed in IIF-ANA. SN - 1437-160X UR - https://www.unboundmedicine.com/medline/citation/30972541/Clinical_use_of_anti_DFS70_autoantibodies_ DB - PRIME DP - Unbound Medicine ER -